Eiki Kikuchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eiki Kikuchi has a total of 155 co-authors. Here are the top co-authors by number of shared publications:
- Masaharu Nishimura
Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Japan; Hokkaido Medical Research Institute for Respiratory Diseases, Sapporo, Japan
10 shared publications Junko Kikuchi
Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Japan
9 shared publications- Jun Sakakibara-Konishi
Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo, 060-8638, Japan; Medical Network and Welfare Center, Hokkaido University Hospital, North 15, West 7, Kita-ku, Sapporo, 060-8638, Japan
8 shared publications - Alexander J. Federation
Altius Institute for Biomedical Sciences
6 shared publications - Carla Bender Kim
Department of Genetics, Harvard Medical School, Boston, MA, USA
6 shared publications - Charles M. Perou
University of North Carolina at Chapel Hill 1 Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina
6 shared publications
Latest Publications
- Open Access
- 14 May 2026
- Published by Wiley in Cancer Science
- Vol. 117 (7) , 1935-1947
Atezolizumab + Chemotherapy in Older Patients With Lung Cancer in Japan
Pivotal phase 3 trials leading to the approvals of atezolizumab─chemotherapy combinations for non‐small cell and extensive‐stage small cell lung cancer (NSCLC and ES‐SCLC) had strict eligibility criteria. J‐TAIL‐2 was a prospective, observational study in Japan that evaluated atezolizumab regimens for advanced NSCLC/ES‐SCLC, including patients ineligible for global trials. The primary endpoint was 12‐month overall survival (OS); safety and efficacy in subgroups defined by age, ECOG PS and/or G8 score, and creatinine clearance were key secondary endpoints. As of February 3, 2023, 1217 patients were treated in clinical practice based on Japanese labeling/treatment guidelines. Patients received atezolizumab with either carboplatin and nab‐paclitaxel (atezo + CnP), carboplatin/cisplatin and pemetrexed (atezo + PP), or bevacizumab and carboplatin and paclitaxel (atezo + bev + CP) in the NSCLC cohort ( n = 814) or with carboplatin and etoposide (atezo + CE) in the ES‐SCLC cohort ( n = 403). Overall, 53.5% were ≥ 70 years old, and 11.8% had ECOG PS ≥ 2; median G8 scores were 13 (NSCLC cohort) and 12 (ES‐SCLC). Patients < 70 and ≥ 70 years had similar median (m)OS and progression‐free survival (mPFS) across treatment regimens. Patients with ECOG PS < 2 and G8 score ≥ median had the highest mOS/PFS vs. patients with ECOG PS ≥ 2 and G8 scoreTrial Registration: ClinicalTrials.gov : NCT04501497
- 14 May 2026
- Published by Wiley in Cancer Science
- Vol. 117 (7) , 1935-1947
Open AccessAtezolizumab + Chemotherapy in Older Patients With Lung Cancer in Japan
Pivotal phase 3 trials leading to the approvals of atezolizumab─chemotherapy combinations for non‐small cell and extensive‐stage small cell lung cancer (NSCLC and ES‐SCLC) had strict eligibility criteria. J‐TAIL‐2 was a prospective, observational study in Japan that evaluated atezolizumab regimens for advanced NSCLC/ES‐SCLC, including patients ineligible for global trials. The primary endpoint was 12‐month overall survival (OS); safety and efficacy in subgroups defined by age, ECOG PS and/or G8 score, and creatinine clearance were key secondary endpoints. As of February 3, 2023, 1217 patients were treated in clinical practice based on Japanese labeling/treatment guidelines. Patients received atezolizumab with either carboplatin and nab‐paclitaxel (atezo + CnP), carboplatin/cisplatin and pemetrexed (atezo + PP), or bevacizumab and carboplatin and paclitaxel (atezo + bev + CP) in the NSCLC cohort ( n = 814) or with carboplatin and etoposide (atezo + CE) in the ES‐SCLC cohort ( n = 403). Overall, 53.5% were ≥ 70 years old, and 11.8% had ECOG PS ≥ 2; median G8 scores were 13 (NSCLC cohort) and 12 (ES‐SCLC). Patients < 70 and ≥ 70 years had similar median (m)OS and progression‐free survival (mPFS) across treatment regimens. Patients with ECOG PS < 2 and G8 score ≥ median had the highest mOS/PFS vs. patients with ECOG PS ≥ 2 and G8 scoreTrial Registration: ClinicalTrials.gov : NCT04501497
- Open Access
- 21 April 2026
- Published by Wiley in Cancer Science
- Vol. 117 (7) , 1948-1960
Plasma Protein Analysis for Biomarker Discovery in Lung Cancer Treated With Atezolizumab Combination Therapy in J‐ TAIL ‐2
J‐TAIL‐2 evaluated the efficacy and safety of atezolizumab, an anti–programmed death‐ligand 1 (PD‐L1), plus chemotherapy in patients with non‐small cell lung cancer (NSCLC) and extensive‐stage small cell lung cancer (ES‐SCLC) in Japanese clinical practice, demonstrating comparable outcomes to those in the corresponding Phase 3 trials. Although PD‐L1 expression is predictive of atezolizumab efficacy in some settings, additional minimally invasive, blood‐based biomarkers are needed. This exploratory biomarker study included 359 J‐TAIL‐2 patients. The NSCLC cohort received atezolizumab combined with carboplatin and nab‐paclitaxel (CnP, n = 42), cisplatin/carboplatin and pemetrexed ( n = 72), or bevacizumab plus carboplatin and paclitaxel (bev + CP, n = 135). The ES‐SCLC cohort received atezolizumab plus carboplatin and etoposide ( n = 100). Approximately 560 cancer‐ or immune‐related proteins were evaluated using the Proximity Extension Assay from blood plasma collected at three timepoints: baseline, before the second atezolizumab dose, and at the onset of immune‐related adverse events (irAEs). Protein‐wise comparisons were made to evaluate significant changes ( P < 0.05 and > 0.5 log2 fold change) and linked to clinical outcomes reported in J‐TAIL‐2. IL‐6, MUC‐16, and KRT‐19 were associated with shorter progression‐free survival across multiple regimens. Granzyme A and B, immune activation markers, were elevated in responders who received atezolizumab + CnP and atezolizumab + bev + CP. High levels of baseline immune stimulation proteins were associated with irAEs across regimens. Protein expression changes were varied and regimen‐dependent in subgroup analyses including older patients and those with EGFR ‐mutant tumors. These data warrant further investigation across different cancer types and atezolizumab‐containing regimens to determine their relevance to efficacy and irAE occurrence of atezolizumab combination therapy. Trial Registration: ClinicalTrials.gov ID, NCT04501497 (J‐TAIL‐2) and NCT04818983 (biomarker study)
- 21 April 2026
- Published by Wiley in Cancer Science
- Vol. 117 (7) , 1948-1960
Open AccessPlasma Protein Analysis for Biomarker Discovery in Lung Cancer Treated With Atezolizumab Combination Therapy in J‐ TAIL ‐2
J‐TAIL‐2 evaluated the efficacy and safety of atezolizumab, an anti–programmed death‐ligand 1 (PD‐L1), plus chemotherapy in patients with non‐small cell lung cancer (NSCLC) and extensive‐stage small cell lung cancer (ES‐SCLC) in Japanese clinical practice, demonstrating comparable outcomes to those in the corresponding Phase 3 trials. Although PD‐L1 expression is predictive of atezolizumab efficacy in some settings, additional minimally invasive, blood‐based biomarkers are needed. This exploratory biomarker study included 359 J‐TAIL‐2 patients. The NSCLC cohort received atezolizumab combined with carboplatin and nab‐paclitaxel (CnP, n = 42), cisplatin/carboplatin and pemetrexed ( n = 72), or bevacizumab plus carboplatin and paclitaxel (bev + CP, n = 135). The ES‐SCLC cohort received atezolizumab plus carboplatin and etoposide ( n = 100). Approximately 560 cancer‐ or immune‐related proteins were evaluated using the Proximity Extension Assay from blood plasma collected at three timepoints: baseline, before the second atezolizumab dose, and at the onset of immune‐related adverse events (irAEs). Protein‐wise comparisons were made to evaluate significant changes ( P < 0.05 and > 0.5 log2 fold change) and linked to clinical outcomes reported in J‐TAIL‐2. IL‐6, MUC‐16, and KRT‐19 were associated with shorter progression‐free survival across multiple regimens. Granzyme A and B, immune activation markers, were elevated in responders who received atezolizumab + CnP and atezolizumab + bev + CP. High levels of baseline immune stimulation proteins were associated with irAEs across regimens. Protein expression changes were varied and regimen‐dependent in subgroup analyses including older patients and those with EGFR ‐mutant tumors. These data warrant further investigation across different cancer types and atezolizumab‐containing regimens to determine their relevance to efficacy and irAE occurrence of atezolizumab combination therapy. Trial Registration: ClinicalTrials.gov ID, NCT04501497 (J‐TAIL‐2) and NCT04818983 (biomarker study)
- Open Access
- 11 December 2025
- Published by Wiley in Cancer Science
- Vol. 117 (3) , 727-738
Atezolizumab + Chemotherapy for Advanced Non‐Small Cell Lung Cancer in Japanese Clinical Practice (J‐TAIL‐2)
First‐line atezolizumab combination therapies were approved for the treatment of metastatic non‐small cell lung cancer (NSCLC) based on results from the global phase 3 trials IMpower130, IMpower132, and IMpower150. These trials reported 12‐month overall survival (OS) rates of 60%–67% with atezolizumab combination therapy. J‐TAIL‐2 (NCT04501497), a prospective, multicenter, observational study, evaluated atezolizumab combination therapy in routine clinical practice in Japan. Patients ≥ 20 years old with NSCLC received atezolizumab plus carboplatin and nab‐paclitaxel (atezo + CnP), atezolizumab plus carboplatin or cisplatin plus pemetrexed (atezo + PP), or atezolizumab plus bevacizumab plus carboplatin and paclitaxel (atezo + bev + CP) in clinical practice. The primary endpoint was the 12‐month OS rate. Secondary endpoints included OS, progression‐free survival, and subgroup analyses, including IMpower‐unlike (did not meet the main eligibility criteria of each IMpower trial) and IMpower‐like patients. In total, 814 patients were enrolled (atezo + CnP, n = 217; atezo + PP, n = 211; atezo + bev + CP, n = 386). The IMpower‐unlike group included patients with Eastern Cooperative Oncology Group performance status ≥ 2, autoimmune disease, or interstitial lung disease. Twelve‐month OS rates (95% confidence interval [CI]) were 62.9% (55.8–69.2), 72.1% (65.2–77.9), and 68.3% (63.2–72.9) with atezo + CnP, atezo + PP, and atezo + bev + CP, respectively. OS hazard ratios (95% CI) in the IMpower‐unlike vs. ‐like subgroups were 1.36 (0.91–2.05), 1.08 (0.70–1.68), and 1.49 (1.09–2.06), respectively. No new safety signals were observed. Real‐world efficacy and safety for each atezolizumab combination were comparable to those in the relevant IMpower trials.
- 11 December 2025
- Published by Wiley in Cancer Science
- Vol. 117 (3) , 727-738
Open AccessAtezolizumab + Chemotherapy for Advanced Non‐Small Cell Lung Cancer in Japanese Clinical Practice (J‐TAIL‐2)
First‐line atezolizumab combination therapies were approved for the treatment of metastatic non‐small cell lung cancer (NSCLC) based on results from the global phase 3 trials IMpower130, IMpower132, and IMpower150. These trials reported 12‐month overall survival (OS) rates of 60%–67% with atezolizumab combination therapy. J‐TAIL‐2 (NCT04501497), a prospective, multicenter, observational study, evaluated atezolizumab combination therapy in routine clinical practice in Japan. Patients ≥ 20 years old with NSCLC received atezolizumab plus carboplatin and nab‐paclitaxel (atezo + CnP), atezolizumab plus carboplatin or cisplatin plus pemetrexed (atezo + PP), or atezolizumab plus bevacizumab plus carboplatin and paclitaxel (atezo + bev + CP) in clinical practice. The primary endpoint was the 12‐month OS rate. Secondary endpoints included OS, progression‐free survival, and subgroup analyses, including IMpower‐unlike (did not meet the main eligibility criteria of each IMpower trial) and IMpower‐like patients. In total, 814 patients were enrolled (atezo + CnP, n = 217; atezo + PP, n = 211; atezo + bev + CP, n = 386). The IMpower‐unlike group included patients with Eastern Cooperative Oncology Group performance status ≥ 2, autoimmune disease, or interstitial lung disease. Twelve‐month OS rates (95% confidence interval [CI]) were 62.9% (55.8–69.2), 72.1% (65.2–77.9), and 68.3% (63.2–72.9) with atezo + CnP, atezo + PP, and atezo + bev + CP, respectively. OS hazard ratios (95% CI) in the IMpower‐unlike vs. ‐like subgroups were 1.36 (0.91–2.05), 1.08 (0.70–1.68), and 1.49 (1.09–2.06), respectively. No new safety signals were observed. Real‐world efficacy and safety for each atezolizumab combination were comparable to those in the relevant IMpower trials.
- 17 August 2023
- Published by Taylor & Francis in Cell Cycle
- Vol. 22 (17) , 1854-1864
Inhibition of non-homologous end joining mitigates paclitaxel resistance resulting from mitotic slippage in non-small cell lung cancer
Mitotic slippage, which enables cancer cells to bypass cell death by transitioning from mitosis to the G1 phase without undergoing normal cytokinesis, is one likely mechanism of paclitaxel (PTX) resistance. DNA double-strand breaks (DSBs) in the G1 phase are mainly repaired through non-homologous end joining (NHEJ). Therefore, inhibiting NHEJ could augment the PTX-induced cytotoxicity by impeding the repair of PTX-induced DSBs during the G1 phase following mitotic slippage. We aimed to evaluate the effects of NHEJ inhibition on mitotic slippage after PTX treatment in non-small cell lung cancer (NSCLC). H1299, A549, H1975, and H520 NSCLC cell lines were employed. In addition, A-196 and JQ1 were used as NHEJ inhibitors. H1299 cells were PTX-resistant and exhibited an increased frequency of mitotic slippage upon PTX treatment. NHEJ inhibitors significantly augmented the PTX-induced cytotoxicity, DSBs, and apoptosis in H1299 cells. The newly generated PTX-resistant cells were even more prone to mitotic slippage following PTX treatment and susceptible to the combined therapy. Docetaxel further demonstrated synergistic effects with the NHEJ inhibitor in PTX-resistant cells. NHEJ inhibition may overcome intrinsic or acquired PTX resistance resulting from mitotic slippage by synergistically increasing the cytotoxic effects of antimitotic drugs in NSCLC.
- 17 August 2023
- Published by Taylor & Francis in Cell Cycle
- Vol. 22 (17) , 1854-1864
Inhibition of non-homologous end joining mitigates paclitaxel resistance resulting from mitotic slippage in non-small cell lung cancer
Mitotic slippage, which enables cancer cells to bypass cell death by transitioning from mitosis to the G1 phase without undergoing normal cytokinesis, is one likely mechanism of paclitaxel (PTX) resistance. DNA double-strand breaks (DSBs) in the G1 phase are mainly repaired through non-homologous end joining (NHEJ). Therefore, inhibiting NHEJ could augment the PTX-induced cytotoxicity by impeding the repair of PTX-induced DSBs during the G1 phase following mitotic slippage. We aimed to evaluate the effects of NHEJ inhibition on mitotic slippage after PTX treatment in non-small cell lung cancer (NSCLC). H1299, A549, H1975, and H520 NSCLC cell lines were employed. In addition, A-196 and JQ1 were used as NHEJ inhibitors. H1299 cells were PTX-resistant and exhibited an increased frequency of mitotic slippage upon PTX treatment. NHEJ inhibitors significantly augmented the PTX-induced cytotoxicity, DSBs, and apoptosis in H1299 cells. The newly generated PTX-resistant cells were even more prone to mitotic slippage following PTX treatment and susceptible to the combined therapy. Docetaxel further demonstrated synergistic effects with the NHEJ inhibitor in PTX-resistant cells. NHEJ inhibition may overcome intrinsic or acquired PTX resistance resulting from mitotic slippage by synergistically increasing the cytotoxic effects of antimitotic drugs in NSCLC.